Go Back to Match Results for ""

Phase II open-label global study to evaluate the effect of dabrafenib in combination with trametinib in children and adolescent patients with BRAF V600 mutation positive Low Grade Glioma (LGG) or relapsed or refractory High Grade Glioma (HGG)
Recruitment Status
OpenContact the research team to learn more about this study.
Fields marked with asterisk (*) are required